RxDoctor Payments Data

Gwen Janczyk, PA

Physician Assistant · la Jolla, CANPI 1417022013

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 73.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $13,433 and has fallen 60.7% since, to $5,277 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,409in general payments, 2019–2025

Across 412 payments — averaging $83.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$25K
  • Medtronic$3K
  • Abbott$2K
  • Impulse Dynamics (USA) Inc.$529
  • Actelion Pharmaceuticals US, Inc.$518
  • Novartis$451
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$3381%
  • Speaking & faculty fees$17,60051%
  • Grants$2001%
  • Travel & lodging$5,96517%
  • Food & beverage$10,30730%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,409 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$259,253
Medicare patients
621
Services billed
2,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$278,942
XareltoRivaroxaban55$63,053
MultaqDronedarone Hcl41$56,401
Flecainide Acetate70$2,519
SotalolSotalol Hcl131$1,990
Metoprolol Succinate99$1,788
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,524
Sotalol AfSotalol Hcl18$677
Propafenone Hcl15$643
Diltiazem Hcl33$618
Potassium Chloride11$482
Metoprolol Tartrate34$377
Amiodarone Hcl21$366
Carvedilol21$303
Digoxin13$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$314$278,942280 claims
Johnson & JohnsonXarelto$71$63,05355 claims
Sanofi-aventis U.S. LLCMultaq$28$56,40141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →